SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D - General statement of acquisition of beneficial ownership:
SEC Accession No. 0001193125-20-001515
Filing Date
2020-01-03
Accepted
2020-01-06 08:40:25
Documents
5
Group Members
SUMITOMO DAINIPPON PHARMA CO., LTD.SUMITOVANT BIOPHARMA LTD.

Document Format Files

Seq Description Document Type Size
1 SC 13D d854428dsc13d.htm SC 13D 96295
2 EX-1 d854428dex991.htm EX-99.1 759655
3 EX-2 d854428dex992.htm EX-99.2 196211
4 EX-3 d854428dex993.htm EX-99.3 209627
5 EX-4 d854428dex994.htm EX-99.4 380686
  Complete submission text file 0001193125-20-001515.txt   1644087
Mailing Address 5281 CALIFORNIA AVENUE SUITE 100 IRVINE CA 92617
Business Address 5281 CALIFORNIA AVENUE SUITE 100 IRVINE CA 92617 949-226-6029
Urovant Sciences Ltd. (Subject) CIK: 0001740547 (see all company filings)

IRS No.: 000000000 | State of Incorp.: D0 | Fiscal Year End: 0331
Type: SC 13D | Act: 34 | File No.: 005-90671 | Film No.: 20508137
SIC: 2834 Pharmaceutical Preparations

Mailing Address 27-1, SHINKAWA 2-CHOME CHUO-KU TOKYO M0 104-8260
Business Address 27-1, SHINKAWA 2-CHOME CHUO-KU TOKYO M0 104-8260 813-5543-5142
Sumitomo Chemical Co., Ltd. (Filed by) CIK: 0001798550 (see all company filings)

IRS No.: 980339148 | State of Incorp.: M0 | Fiscal Year End: 0331
Type: SC 13D